Ratings by BofA Securities (Alec Stranahan)
Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
---|---|---|---|---|---|---|---|---|
2/28/2024 | Spring Works Therapeutics | SWTX | Maintain | Buy (N/A) |
|
Details | ||
1/5/2024 | Erasca Inc | ERAS | Downgrade | Neutral (Buy) |
2.16 (2.06) |
-4.63% | Details | |
1/5/2024 | Revolution | RVMD | Upgrade | Buy (Neutral) |
28.03 (32.23) |
14.98% | Details | |
11/15/2023 | Y-mAbs Therapeutics | YMAB | Maintain | Neutral (N/A) |
|
Details | ||
11/15/2023 | MeiraGTx Holdings plc | MGTX | Maintain | Buy (N/A) |
|
Details | ||
5/25/2023 | Krystal Biotech | KRYS | Maintain | Buy (N/A) |
|
Details | ||
5/19/2023 | Xencor, Inc. | XNCR | New Coverage | Buy (N/A) |
26.05 (22.13) |
-15.05% | Details | |
5/15/2023 | Y-mAbs Therapeutics | YMAB | Maintain | Neutral (N/A) |
|
Details | ||
4/19/2023 | Erasca Inc | ERAS | Maintain | Buy (N/A) |
|
Details | ||
12/29/2022 | TG Therapeutics | TGTX | Maintain | Underperform (N/A) |
|
Details | ||
12/15/2022 | Erasca Inc | ERAS | Maintain | Buy (N/A) |
|
Details | ||
12/15/2022 | Y-mAbs Therapeutics | YMAB | Maintain | Neutral (N/A) |
|
Details | ||
12/15/2022 | Galecto | GLTO | Maintain | Buy (N/A) |
|
Details | ||
12/15/2022 | MeiraGTx Holdings plc | MGTX | Maintain | Buy (N/A) |
|
Details | ||
12/15/2022 | Regenxbio Inc. | RGNX | Maintain | Buy (N/A) |
|
Details | ||
12/15/2022 | Novavax | NVAX | Maintain | Underperform (N/A) |
|
Details | ||
12/2/2022 | Y-mAbs Therapeutics | YMAB | Downgrade | Neutral (Buy) |
4.50 (16.26) |
261.33% | Details | |
12/1/2022 | Spring Works Therapeutics | SWTX | New Coverage | Buy (N/A) |
24.18 (49.22) |
103.56% | Details | |
10/10/2022 | Novavax | NVAX | Maintain | Underperform (N/A) |
|
Details | ||
5/20/2022 | TG Therapeutics | TGTX | New Coverage | Underperform (N/A) |
6.04 (15.21) |
151.82% | Details | |
5/20/2022 | Revolution | RVMD | New Coverage | Neutral (N/A) |
15.16 (32.23) |
112.6% | Details | |
5/20/2022 | Turning Point Therapeutics Inc. | TPTX | New Coverage | Buy (N/A) |
35.36 (76.01) |
114.96% | Details | |
5/3/2022 | Hutchison China MediTech Ltd. | HCM | Maintain | Buy (N/A) |
|
Details | ||
1/18/2022 | Krystal Biotech | KRYS | New Coverage | Buy (N/A) |
62.28 (177.93) |
185.69% | Details | |
11/17/2021 | NextCure Inc. | NXTC | Maintain | Underperform (N/A) |
|
Details | ||
5/7/2021 | Y-mAbs Therapeutics | YMAB | Upgrade | Buy (Neutral) |
28.65 (16.26) |
-43.25% | Details | |
1/15/2021 | Esperion Therapeutics | ESPR | Downgrade | Neutral (Buy) |
26.75 (2.68) |
-89.98% | Details | |
1/15/2021 | NextCure Inc. | NXTC | Downgrade | Underperform (Neutral) |
13.07 (2.23) |
-82.94% | Details | |
1/15/2021 | Y-mAbs Therapeutics | YMAB | Downgrade | Neutral (Buy) |
49.98 (28.65) |
-42.68% | Details | |
10/7/2020 | Y-mAbs Therapeutics | YMAB | Maintain | Buy (N/A) |
|
Details | ||
9/15/2020 | MeiraGTx Holdings plc | MGTX | New Coverage | Buy (N/A) |
13.33 (6.07) |
-54.46% | Details | |
1/14/2020 | NextCure Inc. | NXTC | Maintain | Buy (N/A) |
|
Details | ||
11/13/2019 | Neon Therapeutics | NTGN | Downgrade | Neutral (Buy) |
1.88 (3.07) |
63.3% | Details |